BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

XtalPi Files US FDA IND for AI-Designed Gut-Restricted Pan-TRK Inhibitor KQTD-126

This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...

September 28, 2026 | News

Nutshell Therapeutics Secures FDA IND Clearance for AI-Discovered NRF2 Degrader NTS231

Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announc...

September 28, 2026 | News

FDA Approves Mirum and Incyte’s Atebrioz for Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz...

September 28, 2026 | News

Earendil Labs, Genentech Ink $1.5B+ Deal to Develop AI-Driven Bispecific Antibodies

Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member o...

September 25, 2026 | News

Sanyou Bio, NovoCodex Join Forces to Advance Next-Generation ADC Therapeutics

Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointly announced that the two companies have f...

September 25, 2026 | News

Bio-Techne Shareholders Approve Acquisition by Merck KGaA

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne ...

September 25, 2026 | News

European Commission Approves First-in-Class Obicetrapib for LDL-C Reduction

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability...

September 25, 2026 | News

Singapore Approves Wegovy as First Treatment for MASH with Liver Fibrosis

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with ...

September 23, 2026 | News

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

WuXi XDC Achieves GMP Release for Singapore Bioconjugate Manufacturing Site

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

September 23, 2026 | News

NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...

September 23, 2026 | News

Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins

Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...

September 23, 2026 | News

Accro Bio Doses First Patient in Phase IIb Trial of RIPK2 Inhibitor AC-101 for Ulcerative Colitis

Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, an...

September 22, 2026 | News

Specialised Therapeutics, Incyte Expand Partnership to Bring Ruxolitinib Cream to Australia

Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: IN...

September 22, 2026 | News

Stay Connected